FDA approves 1st drug to treat group of rare blood disorders in nearly 14 years
from U.S. Food & Drug Administration
On Sept. 25, the U.S. Food and Drug Administration approved Nucala for adults and children aged 12 years and older with hypereosinophilic syndrome for six months or longer without another identifiable non-blood related cause of the disease.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063